ストックスクリーナーアプリを入手
2.28
8.06%
0.17
アフターアワーズ：
2.30
0.02
+0.88%
前日終値:
$2.11
開ける：
$2.51
24時間の取引高:
7.15M
Relative Volume:
8.30
時価総額：
$132.02M
収益：
$54.77M
当期純損益:
$15.24M
株価収益率:
9.3596
EPS:
0.2436
ネットキャッシュフロー:
$7.24M
1週間 パフォーマンス:
-15.56%
1か月 パフォーマンス:
-11.63%
6か月 パフォーマンス:
-0.44%
1年 パフォーマンス:
-22.45%
1日の値動き範囲:
$2.1501
$2.51
1週間の範囲:
$1.95
$3.05
52週間の値動き範囲:
$1.80
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
名前
Spero Therapeutics Inc
セクター
電話
857-242-1600
住所
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.28 | 132.02M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-23 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-09-29 | 開始されました | Evercore ISI | Outperform |
| 2019-11-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-09-09 | 開始されました | Janney | Buy |
| 2018-02-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 開始されました | BofA/Merrill | Neutral |
| 2017-11-27 | 開始されました | Oppenheimer | Outperform |
| 2017-11-27 | 開始されました | Stifel | Buy |
すべてを表示
Spero Therapeutics Inc (SPRO) 最新ニュース
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics Stock: Antibiotic Development In Focus - Kalkine Media
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections - TradingView
Spero Therapeutics Inc (SPRO) Institutional Confidence - TradingKey
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Benzinga
AlTi Global And 2 Other Promising Penny Stocks To Watch - simplywall.st
Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US - Quiver Quantitative
FDA approves first oral carbapenem for complicated UTIs in adults - Stock Titan
GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections - Moomoo
SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - timothysykes.com
US FDA approves GSK's oral antibiotic for drug-resistant UTIs - Reuters
Spero Therapeutics Approaches Key FDA Decision For Tebipenem HBr In CUTIs - RTTNews
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Inc (SPRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spero Therapeutics Inc (SPRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Spero Therapeutics Inc (SPRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spero Therapeutics Inc (SPRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Spero Therapeutics Stock (US85208T1079): Quiet session keeps focus on fundamentals and pipeline - AD HOC NEWS
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Spero Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls Amid Lack of Revenue - newsline.com
MSN Money - MSN
Spero Therapeutics (SPRO) Slips 2.41% as Stock Tests Key Support at $2.69Dark Pool Volume - newsline.com
Spero Therapeutics (SPRO) Hovers Near Support Amid Modest Decline – Key Levels in FocusCorrective Wave - The Legal Advocate
Spero Therapeutics (SPRO) Jumps 4.9% as Stock Approaches Key Resistance at $3.15Oversold Bounce Ideas - The Legal Advocate
SPRO Technical Analysis | Trend, Signals & Chart Patterns | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics (SPRO) Q1 2026 Earnings: Why the Beat MattersCEO Earnings Statement - Newser
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis - Gotrade
Promising Penny Stocks To Consider In May 2026 - simplywall.st
Is Spero Therapeutics (SPRO) 110.3% Overvalued After Q1 2026 Ear - GuruFocus
Spero Therapeutics 1Q Loss $7.2M >SPRO - Moomoo
Spero Therapeutics Q1 revenue drops on decreased clinical activity - TradingView
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics (NASDAQ: SPRO) leans on GSK-partnered tebipenem ahead June 2026 FDA date - Stock Titan
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spero Therapeutics (SPRO) trims Q1 2026 loss ahead key tebipenem FDA date - Stock Titan
TradingKey - TradingKey
Number of shareholders of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics CEO sells $63,352 in company stock By Investing.com - Investing.com Australia
Spero Therapeutics (SPRO) officer sells shares for RSU tax obligations - Stock Titan
Spero Therapeutics CEO sells $63,352 in company stock - Investing.com India
SPRO: The fleeting Sparrow - Moomoo
No call planned as Spero sets May 13 for Q1 results update - Stock Titan
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewswire
Spero Therapeutics Inc (SPRO) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):